Protected: 2026 Second Quarter — Policy & Advocacy Wrap Up
There is no excerpt because this is a protected post.
External link. We are not responsible for the content.
Read more ↗More From MAPS
MAPS Responds to Report of Progress for MDMA-assisted therapy for PTSD with FDA
August 10, 2026 — The non-profit Multidisciplinary Association for Psychedelic Studies (MAPS) today responded to an A...
Protected: MAPS Publishes Ibogaine Investigator’s Brochure as a Free, Open-Access Resource
There is no excerpt because this is a protected post.
Psychedelic Science 2027 Speaker Submission Invites the Field to Bridge Promise and Practice
June, 25, 2026 — The Multidisciplinary Association for Psychedelic Studies (MAPS) announced the opening of speaker su...
Latest News
What is an “embedded” brain? Johnson & Johnson plans to invest in “neuroplastogen” company Delix; and University of Miami gifts Trump Administration accelerated path to research ibogaine
Plus: Oregon psilocybin program “generally safe,” according to new study, and New Mexico begins accepting psilocybin ...
5 Psychedelic Stories You Should Know This Week
Welcome to The Psychedelic Blog. Bestselling essayist & Psychedelic cultural analyst examining how altered states sha...
Orchidaceaen Ethics 1
On acid, ancient philosophy, and the problem of knowing
Horizons: Perspectives on Psychedelics
Please join us this autumn for the 19th Horizons conference on October 15-17 in New York City. This is one of the imp...
Would You Recognize Abuse in Ceremony? If So, What Do You Do?
"The Psychedelic Seeker's Guide" dives into abusive practitioners and what you should do if you witness abuse in psyc...
Weekly Psychedelic Policy Briefing – August 16, 2026
Resilient Pharmaceuticals has resubmitted its New Drug Application for MDMA-assisted therapy for PTSD, without the ne...